XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Segment Reporting [Abstract]                
Number of reportable segments | segment             1  
Segment Reporting Information [Line Items]                
Revenue from collaborative arrangement $ 0     $ 0     $ 65,343 $ 100,762
Less:                
Research and development expenses 13,333,329     18,733,584     43,945,638 62,734,891
General and administrative 7,877,126     8,613,895     25,465,208 29,395,232
Total operating expenses 21,210,455     27,347,479     69,410,846 92,130,123
Interest income 552,108     1,106,758     1,970,823 3,914,406
Interest expense 0     0     0 (177,833)
Change in fair value of common stock warrant liabilities (22,515,730)     0     (20,680,868) 0
(Loss) gain on investment in affiliated entity (589,618)     324,251     881,886 (136,061)
Net unrealized gain on available-for-sale equity securities 205,259     1,330,811     1,104,782 1,810,868
Other expense, net (1,938,236)     (579,819)     (2,641,901) (1,254,466)
Net loss (45,496,672) $ (23,519,412) $ (19,694,697) (25,165,478) $ (32,237,098) $ (30,469,871) (88,710,781) (87,872,447)
INO-3107                
Less:                
Research and development expenses 3,352,458     7,009,169     10,790,120 25,697,828
INO-3112 And Other Immuno-oncology                
Less:                
Research and development expenses 1,574,238     1,726,382     4,327,081 5,309,964
Other programs                
Less:                
Research and development expenses 96,971           357,884  
Research and development:       (1,119,600)       (292,372)
Engineering and device-related                
Less:                
Research and development expenses 4,323,775     5,602,688     14,470,247 14,192,615
Stock-based compensation                
Less:                
Research and development expenses 302,249     590,211     1,177,331 2,240,800
Other unallocated expenses                
Less:                
Research and development expenses 3,683,638     4,924,734     12,822,975 15,586,056
Reportable Segments                
Segment Reporting Information [Line Items]                
Revenue from collaborative arrangement 0     0     65,343 100,762
Less:                
General and administrative 7,877,126     8,613,895     25,465,208 29,395,232
Total operating expenses 21,210,455     27,347,479     69,410,846 92,130,123
Interest income 552,108     1,106,758     1,970,823 3,914,406
Interest expense             0 (177,833)
Change in fair value of common stock warrant liabilities 22,515,730     0     20,680,868 0
(Loss) gain on investment in affiliated entity (589,618)     324,251     881,886 (136,061)
Net unrealized gain on available-for-sale equity securities 205,259     1,330,811     1,104,782 1,810,868
Other expense, net (1,938,236)     (579,819)     (2,641,901) (1,254,466)
Net loss $ (45,496,672)     $ (25,165,478)     $ (88,710,781) $ (87,872,447)